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Abstract. TheCOVID-19pandemic has now imposed an enormousglobal burden aswell as a largemortality in a short
time period. Although there is no promising treatment, identification of early predictors of in-hospital mortality would be
critically important in reducing its worldwidemortality.We aimed to suggest a predictionmodel for in-hospital mortality of
COVID-19. In this case–control study, we recruited 513 confirmed patients with COVID-19 from February 18 toMarch 26,
2020 from Isfahan COVID-19 registry. Based on extracted laboratory, clinical, and demographic data, we created an in-
hospital mortality predictive model using gradient boosting. We also determined the diagnostic performance of the
proposedmodel including sensitivity, specificity, and area under the curve (AUC) aswell as their 95%CIs.Of 513patients,
therewere 60 (11.7%) in-hospital deaths during the study period. The diagnostic values of the suggestedmodel based on
the gradient boosting method with oversampling techniques using all of the original data were specificity of 98.5% (95%
CI: 96.8–99.4), sensitivity of 100% (95% CI: 94–100), negative predictive value of 100% (95% CI: 99.2–100), positive
predictive value of 89.6% (95% CI: 79.7–95.7), and an AUC of 98.6%. The suggested model may be useful in making
decision to patient’s hospitalization where the probability of mortality may be more obvious based on the final variable.
However, moderate gaps in our knowledge of the predictors of in-hospital mortality suggest further studies aiming at
predicting models for in-hospital mortality in patients with COVID-19.
INTRODUCTION
The COVID-19 with a dramatic worldwide spreading trend
has been caused by the seventh member of the coronavirus
family called SARS-CoV-21 with the ability for human in-
fection.2WithR0 of 1.4–3.58
3,4 and amortality rate of 5.6% for
China and 15.2% for outside of China,5 COVID-19 is now the
third most fatal virus, after SARS-CoV6 and Middle East re-
spiratory syndrome coronavirus (MERS-CoV),7 in the coro-
navirus family. TheWHOhasdeclared its pandemic,8 andasof
October 4, 2020, almost 35 million people had confirmed di-
agnoses of COVID-19, resulting in 1,039,298 deaths world-
wide.9 The epidemic curve is still in its ascending stage in Iran,
and the official number of Iranian patients with COVID-19 and
its resulting deaths were 471,772 and 26,957, respectively.
Isfahan is considered one of the COVID-19 outbreak zones in
Iran.
A number of demographic, clinical, and laboratory variables
including age,10,11 smoking history,12 hypertension,11 di-
abetes, fever,11–13 respiratory rate,13 baseline neutrophil
count,11 albumin,13 lymphocyte count,11,13 white blood cells
(WBC),11 platelet count,11 higher sequential organ failure as-
sessment score,14 dyspnea,13 andbloodD-dimer greater than
1 μg/mL14 have been collected and suggested to play a role in
the primary and secondary outcomes of COVID-19.
In the current COVID-19 pandemic, there are several issues
that still remain controversial and need to be further
investigated. For example, data on the prediction of disease
prognosis are still inconclusive, and health authorities are
concerned about the most important predictors of mortality
from COVID-19. Although there is no cure for the patients
identified with COVID-19 up to now, early finding of patients
with poor prognosis based on a number of characteristics
could have an important role in the COVID-19 outcomes. This
may also assist the health system in more effective resource-
allocating and also in providing more supportive, appropriate,
and on time supportive treatment. Here in, using a case–
control study in IsfahanCOVID-19 registry (I-CORE),weaimed
to investigate the most important risk or protective factors of
in-hospital mortality in Isfahan, Iran.
METHOD
This was a case–control study of 513 Iranian patients with
COVID-19 aged 1–97 years registered in the I-CORE,15 Isfa-
han, Iran. Data on all patients registered from February 18, the
date of the first patient admission, to March 26, 2020 were
obtained.
Participants. Confirmation of patients with COVID-19. We
collected respiratory samples, that is, throat swabs for out-
come ascertainment. The WHO interim guidance16,17 was
used for detecting all patients with COVID-19 pneumonia. We
also used real-time PCR to confirm the COVID-19 infection in
all of the study blood samples.
Study cases. Cases were those patients with COVID-19
who died at the end of hospitalization.
Study controls.We classified those patients with COVID-19
who were alive at the time of discharge as the study controls.
The following criteria were defined as discharge conditions: 1)
return of body temperature to the normal values for ³ 3days, 2)
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observation of apparent inflammatory decrease in the
pulmonary imaging, and3) noticing significant improvement in
the respiratory symptoms.
The data were anonymous, and the study was approved by
the Research Ethics Committee of Isfahan University of
medical science (IR.MUI.MED.REC.1398.733). The Ethics
Committee of Isfahan University of medical science waived
the prerequisite for patients’ informed consent.
Measurements. A trained team of physicians and nurses
as well as medical students reviewed and registered de-
mographic, clinical, laboratory findings, and finally the out-
come data. Using a standardized data collection checklist, we
extracted data on aforementioned variables. Admission data
and outcome (death or discharge) were obtained for all of the
study individuals.
Clinical data. We obtained clinical data at hospital admis-
sion date. Data on medical comorbidities, that is, diabetes,
cancers, cardiovascular disease, neurological disorder,
asthma, HIV/AIDS, chronic blood disease, chronic liver dis-
ease, chronic kidney disease (CKD), other lung disease, and
immunodeficiency, were collected. We also recorded clinical
signs and symptoms including cough, fever, muscle pain,
decreased consciousness, and respiratory distress. Using
digital thermometers, fever was defined as axillary tempera-
ture > 37C or oral temperature > 37.5C.
Laboratory findings. Routine blood examinations, that is,
complete blood count, alanine aminotransferase (ALT), as-
partate aminotransferase (AST), total bilirubin, activated par-
tial thromboplastin time (aPTT), prothrombin time (PT),
international normalized ratio (INR), blood glucose, blood urea
nitrogen (BUN), creatinine, C-reactive protein (CRP), hemat-
ocrit, hemoglobin (HB), lymphocytes percentage, neutrophils
percentage, Na, K, lactic acid dehydrogenase, platelets, and
WBC,were obtained.We also calculated the AST/ALT ratio as
well as categories for all of the aforementioned blood indices
(normal, < normal, and > normal values).
Demographic variables. The checklist also included de-
mographic data, that is, age and gender.
Statistical analysis. Meeting the required assumptions,
that is, normal test using the Kolmogorov–Smirnov test (P >
0.05), we used the independent t-test for continuous variables
and chi-square test for categorical covariates in the bivariate
analysis to compare survivors’ and non-survivors’ de-
mographic, clinical, and laboratory features at the time of
admission. We analyzed the laboratory variables as both
continuous and categorized (less-than-normal, normal, and
more-than-normal values). Where appropriate, by replacing
the binary predictors with a single predictor and taking cate-
gory rank scores, we perform chi-squared tests for trend of
ordinal categorical variables. Logistic regression model was
fitted for determining factors related to in-hospital mortality.
The significance levels in all study tests used in the bivariable
analysis was 0.05. A gradient boosting model was used to
predict mortality and estimate the diagnostic power of the
logistic regression model as well as the relative importance of
each contributor. For the logistic model, we used Akaike in-
formation criteria as well as the Hosmer–Lemeshow test for
model fitting. Furthermore, the contribution and importance of
each variable was estimated. The area under the curve (AUC)
of the suggested model was also calculated. Diagnostic per-
formance of the model, that is, its sensitivity, specificity,
positive predictive value (PPV), and negative predictive value
(NPV), and their 95% CIs were estimated.
Gradient boosting model. The gradient boosting is a ma-
chine learning technique suited to create predictivemodels by
an ensemble of weak predictive models typically logistic re-
gressions or decision trees.18 It is a boosting method that
allows for optimization of a differentiable loss function. As any
other boosting method, it belongs to supervised learning al-
gorithms. To apply this model, we first created two sets from
the input data for training and testing. All of the study variables
were selected based on the literature review as well as the
experts’ comments. Based on the fitting criteria as well as
diagnostic values, the final prediction model including a
combination of clinical and laboratory variables was pro-
posed. The default value of 0.5was used for the value at which
predicted probabilities are assigned to binary outcomes in
both of the gradient boosting and logistic model. The relative
importance of each contributor in the suggested model was
estimated using the “varImp” function from the “caret” library
in R.18
Balancing techniques. Using both oversampling and
under-sampling methods, we repeated the whole of the
analysis steps. We used the “upSample” and “downSample”
functions, both from the “caret” package, to obtain an over-
sampled and under-sampled datasets, respectively. Then, we
used the “createDataPartition” to obtain a train (80%) and test
(20%) on each dataset.19 The gradient boost implementation
used, that is “xgbtree,” was the one included in the “caret”
package and had receiver operating characteristic (ROC) as
the optimization metric (for more information, see Appendix).
We trained the gradient boosting model using the train data.
We also validated the models in two ways: first, using the test
set created for each dataset (test set of oversampled and test
set of under-sampled), and second, we used all the original
data. The specificity, sensitivity, PPV, and NPV figures re-
ported correspond to the oversampling experiment model,
and hasbeen validated using all the original data.While under-
sampling approach might be an option, because of the small
number of death cases, the under-sampled training set had
only 96 individuals, which is very poor to train a gradient
boosting model. On the other hand, the oversampling ap-
proach led to a train set of 726 individuals which was large
enough. This approach takes into account themissing values,
and for this reason, it is robust enough to capture the sensi-
tivity of 100%.Although the oversampled test setmight not be
representative enough, validation was performed using both
test set and all of the original data. For more information, see
supplemental material.
Sample size calculation. For developing multivariable
predictionmodels, the ratio of events per variable (EPV) would
possibly be a practical criterion for sample size calculation.
Simulation studies have suggested EPV values of between
five and 20.20 Considering the rarity of event, that is, death in
COVID-19 and the 12 included predictors in the final model
and aminimum of five EPV, we employed 513 patients with 60
events minimum in this study.
RESULTS
We enrolled 513 patients with COVID-19 between February
18 and March 26, 2020․ All patients had well-known final in-
hospital outcomes, and, of them, 60 (11.7%) died during
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hospitalization. The median age was 61 years, and the mean
(SD) age of survivors was 57.1 (16.9) years and was signifi-
cantly lower than that of non-survivors, that is, 71.3 (13.4), P <
0.001. Gender was not significantly different between the
study groups (P = 0.399). The mean (SD) intensive care unit
(ICU) days were significantly higher in dead subjects (5.4 [5.0]
versus 0.6 [2.4], P < 0.001). Among comorbidities, there was a
statistically significant difference between the study groups in
the case of chronic kidney disease (8.3% in dead versus 2.9%
in survivors, P = 0.039). For clinical signs and symptoms, we
also found that a higher proportion of survivors were hospi-
talized with cough as the signs and symptoms of COVID-19
(P = 0.033). Moreover, the proportion of thosewith ³ 2 primary
signsofCOVID-19wassignificantly higher in the survivors (P=
0.038) (Table 1).
Table 2 demonstrated the unadjusted associations be-
tween laboratory variables and final in-hospital mortality. Ex-
cept for blood glucose, platelets, CRP, and PT, we observed a
significant association between the other laboratory variables
and in-hospital mortality in the bivariable analysis (P < 0.05).
Less-than-normal values of lymphocytes percentage had the
strongest association with mortality (odds ratio [OR] = 7.98;
95% CI: 3.52–18.09, P < 0.001), followed by more-than-
normal values of BUN (OR = 7.11; 95% CI: 3.95–12.81, P <
0.001), more-than-normal values of creatinine (OR = 6.49;
95%CI: 3.63–11.60,P< 0.001), andmore-than-normal values
of HB (OR = 5.30, 95% CI: 1.32–21.28, P = 0.019). In-
terestingly, apparent dose–response patternwas detected for
categories of hematocrit, HB, WBC, lymphocytes, and neu-
trophils (Table 2).
There was complete laboratory data on 252 patients.
Moreover, clinical and demographic variables were also
complete for these 252 patients. The suggested model
(n = 252) was based on laboratory variables, that is, neutro-
phils’ percentage, PT, hematocrit, CRP, aPTT, BUN, creati-
nine, and AST/ALT along with a number of clinical variables,
that is, respiratory distress and age. In the multivariable lo-
gistic regression analysis, neutrophil percentage (OR = 1.37;
95% CI: 1.02–1.83, P = 0.035), PT (OR = 1.09; 95% CI:
1.02–1.17, P = 0.012), and less-than-normal values of he-
matocrit (OR = 6.03; 95% CI: 1.02–35.75, P = 0.048) signifi-
cantly increased the risk of in-hospital mortality. The other
remaining variables significantly increased the diagnostic
power of the final suggested model. The relative importance
of variables for prediction of in-hospital mortality in the final
model is demonstrated in Figure 1. Blood urea nitrogen
was the most important predictor of mortality followed by
AST/ALT ratio, neutrophil percentage, and aPTT. The values
of the suggested model based on the gradient boosting
method with oversampling techniques using all of the
TABLE 1
Demographic and clinical characteristics of patients with COVID-19 by in-hospital mortality in total sample and age-groups, Isfahan, Iran, 2020
Total sample Age-groups
Survivors Non-survivors Unadjusted OR, 95% CI*, P-value
Unadjusted OR, 95% CI*, P-value
£ 60 > 60
Mean age (SD) 57.08 (16.96) 71.3 (16.37) 1.06 (1.04, 1.08), < 0.001 0. 99 (0.94, 1.05), 0.926 1.07 (1.03, 1.11), < 0.001
Median age 58 74 - – –
Gender (male), N (%) 261 (57.62) 38 (63.33) 1.27 (0.73, 2.22), 0.399 1.24 (0.37, 4.09), 0.728 1.24 (0.66, 2.35), 0.501
Medical history variables, n (%)
Cancer (yes) 13 (2.87) 2 (3.33) 1.17 (0.26, 5.30), 0.841 1.88 (0.09, 36.05), 0.676 1. 26 (0.30, 5.34), 0.754
HIV/AIDS (yes) 2 (0.44) 0 (0) 1.49, (0.07, 31.45), 0.797 7.00 (0.27, 181.40), 0.241 1. 42 (0.06, 35.32), 0.832
Asthma (yes) 13 (2.87) 1 (1.67) 0.57 (0.07, 4.46), 0.596 5.20 (0.79, 34.06), 0.086 0.27 (0.01, 4.90), 0.380
Chronic neurologic
disorder (yes)
9 (1.99) 0 (0) 0.39, (0.02, 6.73), 0.514 2.30 (0.12, 45.41), 0.583 0.38 (0.02, 6.97), 0.514
Cardiovascular disease
(yes)
69 (15.23) 9 (15.00) 0.98 (0.46, 2.09), 0.963 1.47 (0.25, 8.61), 0.668 0.69 (0.31, 1.54), 0.367
Blood chronic disease (yes) 5 (2.02) 0 (0) 0.51, (0.027, 9.33), 0.647 7.48 (0.27, 205.51), 0.234 0.32 (0.02, 6.11), 0.450
Chronic liver disease (yes) 4 (0.88) 0 (0) 0.82, (0.04, 15.52), 0.898 2.97 (0.14, 61.07), 0.479 1.42 (0.57, 35.32), 0.832
Diabetes (yes) 61 (13.47) 11 (18.33) 1.44 (0.71, 2.93), 0.355 1.27 (0.22, 7.41), 0.787 1.24 (0.57, 2.66), 0.587
Chronic kidney disease
(yes)
13 (2.87) 5 (8.33) 3.08 (1.06, 8.96), 0.039 6.17 (0.91, 41.59), 0.062 2.37 (0.72, 7.56), 0.155
Other chronic disease (yes) 65 (14.35) 10 (16.67) 1.19 (0.58, 2.47), 0.633 2. 98 (0.81, 10.97), 0.100 0. 85 (0.36, 1.99), 0.706
Immune deficiency (yes) 4 (0.88) 0 (0) 0.84, (0.045, 15.79), 0.907 2. 97 (0.14, 61.07), 0.479 1.45 (0.06, 36.06), 0.822
Total comorbidities, n (%)
0 286 (63.13) 31 (52.54) 1 1 1
1 104 (22.96) 19 (32.20) 1.68 (0.91, 3.11), 0.095 1.47 (0.34, 6.40), 0.608 1.20 (0.60, 2.39), 0.600
³ 2 63 (13.91) 9 (15.25) 1.32 (0.60, 2.90), 0.494 2.43 (0.55, 10.80), 0.244 0.84 (0.34, 2.06), 0.704
Signs and symptoms at admission date, n (%)
Total signs and symptoms 1.75 (1.07) 1.63 (1.25) 0.90 (0.70, 1.16), 0.425 1.18 (0.66, 2.13), 0.571 0.84 (0.64, 1.11), 0.228
Categorized total signs and symptoms
None 74 (16.34) 17 (28.33) 1 1 1
1 81 (17.88) 8 (13.33) 0.43 (0.17, 1.05), 0.065 0.20 (0.01, 4.40), 0.311 0.44 (0.17, 1.15), 0.094
³ 2 298 (65.78) 35 (58.33) 0.51 (0.27, 0.96), 0.038 0.98 (0.23, 4.10), 0.974 0.42 (0.20, 0.86), 0.019
Fever 238 (52.54) 26 (43.33) 0.69 (0.40, 1.19), 0.182 1.11 (0.34, 3.54), 0.865 0.60 (0.32, 1.13), 0.113
Muscle pain 115 (25.39) 13 (21.67) 0.81 (0.42, 1.56), 0.532 0.71 (0.17, 2.95), 0.641 0.95 (0.46, 1.98), 0.902
Cough 248 (54.75) 24 (40.00) 0.55 (0.32, 0.95), 0.033 1.86 (0.52, 6.64), 0.337 0.44 (0.23, 0.65), 0.014
Decreased consciousness 8 (1.77) 3 (5.00) 2.93 (0.75, 11.35), 0.120 7.00 (0.27, 181.40), 0.241 2.05 (0.55, 7.59), 0.281
Respiratory distress 185 (40.84) 32 (53.33) 1.65 (0.96, 2.84), 0.068 1.48 (0.46, 4.74), 0.512 1.43 (0.77, 2.66), 0.253
OR = odds ratio. The bold values are significant at 0.05 level.
* In the case of sparse data, the OR (95% CI) was calculated using the penalized likelihood estimator.
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TABLE 2
Laboratory characteristics of patients with COVID-19 by in-hospital mortality, Isfahan, Iran, 2020
Laboratory variable* Survivors, n (%) Non-survivors, n (%) Unadjusted OR, 95% CI† P-value
Mean ALT (SD) 34.60 (36.50) 39.88 (43.00) 1.00 (0.99, 1.01) 0.393
Categorized ALT (IU/L)
7–55 250 (86.21) 34 (79.07) 1 –
< 7 2 (0.69) 0 (0) 1.45 (0.07, 30.88) 0.811
> 55 38 (13.10) 9 (20.93) 1.79 (0.81, 3.96) 0.150
Test for trend – – 1.33 (0.89, 1.98) 0.163
Mean AST (SD) 49.83 (60.68) 67.86 (58.80) 1.00 (0.99, 1.01) 0.130
Categorized AST (U/L)
8–48 211 (86.21) 21 (79.07) 1 –
< 8 0 (0) 0 (0) – –
> 48 79 (0.69) 21 (0) 2.67 (1.38, 5.16) 0.003
AST/ALT ratio (IU/L) 1.75 (1.28) 2.07 (1.12) 1.15 (0.94,1.40) 0.167
Neutrophils, n % 70.43 (12.18) 80.60 (12.31) 1.09 (1.06, 1.13) < 0.001
Categorized neutrophils %
55–70 161 (37.18) 8 (14.04) 1
< 50 42 (9.70) 2 (3.51) 0.96 (0.20, 4.68) 0.958
> 70 230 (53.12) 47 (82.46) 4.11 (1.89, 8.93) < 0.001
Test for trend – – 2.13 (1.44, 3.16) < 0.001
Lymphocytes, n% 22.67 (10.62) 14.54 (11.11) 0.91 (0.87, 0.94) < 0.001
Lymphocytes %
20–40 220 (50.57) 7 (12.28) 1 –
< 20 185 (42.53) 47 (82.46) 7.98 (3.52, 18.09) < 0.001
> 40 30 (6.90) 3 (5.26) 3.14 (0.77, 12.81) 0.110
Test for trend – – 2.56 (1.64, 4.01) < 0.001
Mean blood urea nitrogen (SD) 17.63 (10.42) 33.75 (24.20) 1.08 (1.05–1.10) < 0.001
Categorized blood urea nitrogen (mg/dL)
6–25 358 (84.83) 26 (45.61) 1 –
< 6 4 (0.95) 0 (0) 1.50 (0.08, 28.70) 0.786
> 25 60 (14.22) 31 (54.39) 7.11 (3.95, 12.81) < 0.001
Mean creatinine (SD) (mg/dL) 1.12 (0.50) 1.84 (1.32) 2.59 (1.82, 3.68) < 0.001
Categorized creatinine (mg/dL)
For male: 0.7–1.3 365 (83.52) 25 (43.86) 1 –
For female: 0.4–1.1
For male: < 0.7 0 (0) 0 (0) – –
For female: < 0.4
For male: > 1.3 72 (16.48) 32 (56.14) 6.49 (3.63, 11.60) < 0.001
For female: > 1.1
Mean WBC (SD) (cells/L), 5,816.05 (2,692.70) 8,403 (4,303.5) 1.0002 (1.0001, 1.0003) < 0.001
Categorized WBC (cells/L)
4,000–10000 310 (68.43) 39 (66.10) 1 –
< 4,000 111 (24.50) 3 (5.08) 0.21 (0.06, 0.71) 0.012
> 10000 32 (7.06) 17 (28.81) 4.22 (2.15, 8.30) < 0.001
Test for trend – – 1.62 (1.12, 2.34) 0.009
Mean aPTT (SD) (sec) 35.77 (12.91) 42.59 (18.11) 1.02 (1.01, 1.04) 0.003
Categorized aPTT (sec)
30–45 198 (58.41) 32 (65.31) 1 –
< 30 104 (30.68) 6 (12.24) 0.36 (0.14, 0.88) 0.025
> 45 37 (10.91) 11 (22.45) 1.84 (0.85, 3.97) 0.121
Test for trend – – 1.09 (0.71, 1.66) 0.691
Mean CRP (SD) (mg/L) 46.12 (72.66) 59.81 (57.55) 1.002 (0.998, 1.005) 0.333
Categorized CRP (mg/L)
< 10 52 (17.99) 4 (12.50) 1 –
> 10 237 (82.01) 28 (87.50) 1.53 (0.51, 4.57) 0.440
Mean Hematocrit (SD) 41.81 (5.83) 39.21 (7.06) 0.92 (0.88, 0.97) 0.001
Categorized hematocrit
For male: 42–54 (% L/L) 271 (60.63) 18 (30.00) 1 –
For female: 38–46%
For male: < 42% 159 (35.57) 37 (61.67) 3.50 (1.93, 6.36) < 0.001
For female: < 38%
For male: > 54% 17 (3.80) 5 (8.33) 4.43 (1.47, 13.37) 0.008
For female: > 46%
Test for trend – – 2.58 (1.67, 4.01) < 0.001
Mean HB (SD) 13.47 (1.81) 12.58 (2.50) 0.79 (0.70, 0.91) 0.001
Categorized HB (mg/dL)
For male: 14–17.4 286 (63.13) 18 (30.00) 1 –
For female: 12–16
For male: < 14 158 (34.88) 39 (65.00) 3.92 (2.17, 7.08) < 0.001
For female: < 12
For male: > 17.4 9 (1.99) 3 (5.00) 5.30 (1.32, 21.28) 0.019
(continued)
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original data were AUC of 98.6, sensitivity of 100 (95% CI:
94–100), specificity of 98.5% (95%CI: 96.8–99.4), an NPV of
100% (95% CI: 99.2–100), and a PPV of 89.6 (95% CI:
21.2–86.3). The values of the suggested model based on the
gradient boosting method with oversampling techniques
using test set data were AUC of 98.9, sensitivity of 100 (95%
CI: 96.0–100), specificity of 93.3% (95% CI: 86.1–97.5), an
NPVof 100% (95%CI: 95.7–100), and aPPVof 93.8 (95%CI:
86.9–97.7). However, using logistic regression and “estat
classification” command in STATA v. 12 (StataCorp.,
College Station, TX), the obtained diagnostic values were
AUC of 94.1, sensitivity of 64.7 (95% CI: 57.3–72.2), speci-
ficity of 97.9% (95% CI: 95.6–100), NPV of 95.8% (95% CI:
92.7–98.9), and PPV of 78.6 (95% CI: 72.2–85.00) (Table 3).
DISCUSSION
Using data of I-CORE system, we found an in-hospital
mortality of 11.7%. Furthermore, based on early-available
clinical and laboratory data, we suggested a prediction model
TABLE 2
Continued
Laboratory variable* Survivors, n (%) Non-survivors, n (%) Unadjusted OR, 95% CI† P-value
For female: > 16
Test for trend – – 3.12 (1.93, 5.05) < 0.001
AST/ALT ratio 1.75 (1.28) 2.07 (1.12) 1.15 (0.94–1.40) 0.167
Mean platelets (SD) 181,000.15 (71,000.66) 168,000.61 (72,000.31) 0.997 (0.993, 1.001) 0.204
Categorized platelets
140,000–400,000/dL 304 (67.71) 37 (61.67) 1 –
< 140,000/dL 140 (31.18) 23 (38.33) 1.35 (0.78, 2.36) 0.292
> 400,000/dL 5 (1.11) 0 (0) 0.74 (0.04, 13.62) 0.838
Meanbloodglucose (SD) (mg/dL) 143.30 (64.07) 149.95 (79.87) 1.001 (0.995, 1.007) 0.644
Categorized blood glucose (mg/dL)
90–130 104 (50.00) 12 (52.17) 1 –
< 90 18 (8.65) 1 (4.35) 0.48 (0.059, 3.93) 0.495
> 130 86 (41.35) 10 (43.48) 1.01 (0.41, 2.44) 0.986
Test for trend – – 0.999 (0.64, 1.57) 0.998
Mean PT (SD) (sec) 13.27 (3.79) 16.53 (16.71) 1.04 (1.001, 1.09) 0.047
Categorized PT (sec)
10–12 97 (30.99) 16 (31.37) 1 –
< 10 2 (0.64) 0 (0) 1.18 (0.05, 25.73) 0.915
> 12 214 (68.37) 35 (68.63) 0.99 (0.524, 1.88) 0.979
ALT= alanine aminotransferase; aPTT = activated partial thromboplastin time; AST = aspartate aminotransferase; CRP=C-reactive protein; HB= hemoglobin; OR=odds ratio; PT = prothrombin
time. The bold values are significant at 0.05 level.
* The categories were created based on specific values for each variable, that is, normal, less than normal, and more than normal.
† In the case of sparse data, the OR (95% CI) was calculated using the penalized likelihood estimator.
FIGURE 1. Variable importance for gradient boosting model using the “varImp” function.
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for in-hospital mortality with an AUC of 98.6%. In term of rel-
ative importance, lymphocyte percentage, higher BUN, aPTT,
neutrophil percentage, and age were the most important
variables for prediction of in-hospital mortality in patients with
COVID-19. Moreover, a higher AST/ALT ratio, CRP, PT, he-
matocrit, and respiratory distress were all among the top 10
important predictors of mortality.
The in-hospitalmortality reported in this study ismoderately
higher than that (7.2%) reported by Kun Wang11 in Wuhan,
China. Several factors including the hospital referral time or
the disease severity at the time of admission may be re-
sponsible for this difference. Among 10 reported important
factors of in-hospital mortality in our study, there are five in
commonwith KunWang study, that is, neutrophil percentage,
aPTT, CRP, age, and lymphocyte percentage in. Although
neutrophil percentage was reported as the most important
predictor of mortality in Wuhan, here, with relative importance
of around 13%, it is the fourth most important predictor in our
study. We reported lymphocyte percentage and higher BUN
as the first two most important predictors in our analysis.
However, these two factors were not reported before.11
C-reactive protein level is described in both studies as the fifth
most important predictor of mortality.
The prevalence of CKD was significantly higher in non-
survivors.Consistentwithour findings,Chenget al.21 reported
a statistically significant association between kidney disease
and elevated risk of in-hospital death in a prospective cohort
study of 701 patients with COVID-19 in Wuhan. Acute renal
failure has been reported in 0.5–7%of COVID-19 cases and in
2.9–23% of ICU patients.12,21,22 There is little evidence of
direct kidney injury by SARS-CoV-2; however, kidney in-
volvement is common in complications of acute respiratory
distress syndrome (ARDS). Pan et al.23 have shown potential
vulnerability of podocytes and proximal tubule cells through
SARS-CoV-2–angiotensin-converting enzyme-2 interaction
by single-cell RNA-seq analysis.24 Cytokine damage and
kidney failure secondarily to lung injury could be the other
possible mechanisms.25 Liver injury and failure following
critical illnesses such as ARDS have been reported in up to
20% of ICU patients and are associated with significantly in-
creasedmorbidity and mortality. The underlying mechanisms
may be hypoxic, inflammatory, or drug induced.26
In line with the results of a hospital-based case–cohort
study on 200COVID-19 patients inWuhan, China,27 we found
a positive but statistically insignificant association between
higher values of AST/ALT ratio and in-hospital mortality. Fur-
thermore, we found that the baseline AST/ALT ratio, a marker
of hepatic injury,28 would be a strong predictor of mortality in
the gradient boosting model. Although the elevated level of
AST and ALT in patients with COVID-19 has been formerly
reported,29,30 here,wealsohighlighted theprognostic valueof
AST/ALT in COVID-19 mortality.
Higher values of neutrophil percentage were associated
with increased risk of mortality. This finding supports the
previously reported results of a study on 61 patients with
2019-nCoV at Beijing Ditan Hospital.31 Although neutrophils
have an important role at the time of infection, neutrophil
infiltration might be a proxy for harmful inflammatory
processes. We found that elevated aPTT may play a role in
poor outcomes in patients with COVID-19. This is consistent
TABLE 3
Multivariable logistic regression models of in-hospital mortality in patients with COVID-19, Isfahan, Iran, 2020
Predictor Odds ratio (95% CI) P-value
Neutrophils
percentage
1.37 (1.02, 1.83) 0.035
Prothrombin time 1.09 (1.02, 1.17) 0.012
Categorized
hematocrit
Less than normal 6.03 (1.02, 35.75) 0.048
More than normal 3.86 (0.19, 77.18) 0.377
C-reactive protein 1.01 (0.99, 1.03) 0.244
Activated partial
thromboplastin time
1.01 (0.96, 1.06) 0.711









1.42 (0.43, 6.49) 0.453
Respiratory distress 2.89 (0.49, 17.17) 0.243
Hemoglobin 1.11 (0.66, 1.86) 0.704
Age 1.03 (0.97, 1.09) 0.292
Measures of model
performance
Logistic model Gradient boosting model using all of the
original data
Gradient boosting model using test set
data
Specificity 97.9% (95% CI: 95.6–100) 98.5% (95% CI: 96.8–99.4) 93.3% (95% CI: 86.1–97.5)
Negative predictive
value
95.8% (95% CI: 92.7–98.9) 100% (95% CI: 99.2–100) 100% (95% CI: 95.7–100)
Sensitivity 64.7% (95% CI: 57.3–72.2) 100% (95% CI: 94–100) 100% (95% CI: 96.0–100)
Positive predictive
value
78.6% (95% CI: 72.2–85) 89.6% (95% CI: 79.7–95.7) 93.8% (95% CI: 86.9–97.7)
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with the findings of Songping Cui et al.32 that reported sig-
nificant prolongation of PT and aPTT as a reliable factor for
identifying high-risk groups of patients with severe COVID-
19. COVID-19 coagulopathy reflected by thrombocytopenia,
prolongation of the PT/INR, PTT, elevation of D-dimer, and
decreased fibrinogen levels could lead to disseminated in-
travascular coagulation (DIC).33 Tang et al.34 have shown
that DIC in COVID-19 patients is associated with a higher
mortality rate. A strong inflammatory index, CRP, was iden-
tified as one of the predictors of mortality in this study. It is
now well accepted that CRP levels generally increase in
patients with severe COVID-19 even at its initial stages.
Moreover, it is positively correlated with lung damage and
could predict disease severity.35,36
In line with the findings of previous studies,11,13,14 older age
was associated with an increase in the odds of mortality. Fi-
nally, among signs and symptoms on admission, respiratory
distress was one of the 10 predictors of mortality.
Wynants et al.37 in a systematic review highlighted that the
currently suggested models for mortality from COVID-19 are
poorly reported and had been suffered from some degree of
bias.
The lack of differences in comorbidities and also the
number of comorbidities between the survivor and non-
survivor groups, apart from CKD, are a surprising result,
given the existing literature. However, the OR (95% CI)
shown in Table 1 are unadjusted one, and it would be sta-
tistically possible to find different or even a significant P-
value if one would investigate the adjusted associations.
Although the study’s main objective was to propose a pre-
diction model not adjusted ORs, we have not investigated
such associations. Moreover, it is likely that hospital ad-
mission policy as well as referral patterns of patients with
COVID-19 in Iran has been suffered from some degree of
bias, that is, a subgroup of patients with high prevalence and
history of illnessesmore likely referred to hospitals and had a
higher chance of hospital admission. Therefore, both survi-
vors and non-survivors with a higher history of comorbidities
were more likely hospitalized during the pandemic. We only
reported the mortality in those hospitalized patients. More-
over, as the outcome of this study was in-hospital mortality,
the real long-term risk ofmortality would be different than the
estimated risk in this study. The possibility and magnitude of
imposed bias on the estimated risk of mortality cannot be
predictable without sufficient information about the referral
pattern of patients and its associated factors. Because of the
retrospective nature of the study design, we only analyzed
laboratory data of 252 patients because of the lack of com-
plete information for all of the study subjects. This might
decrease the precision of the study estimates. Moreover,
data on D-dimer were not available for analysis, and the es-
timated results have not been adjusted for its effect in the
final suggested model. The obtained sensitivity of the sug-
gested model was low. One of the possible reasons is the
high imbalance of dead and alive individuals in our sample,
with an extremely higher proportion of alive discharged pa-
tients. Rare event bias could explain the low obtained sen-
sitivity of the proposed model. The lower the proportion of
the study events, the lower the predictive accuracy for events
and the higher the predictive accuracy for nonevents.38
Nonetheless, we consider that this is a useful model for
clinical practice as it has a high specificity of 95.6% and a
high NPV of 92.5%. This means that our model correctly
classifies those patients who survived from COVID-19. This
is especially important to prioritize resources in health ser-
vices, especially when the financial and human resources are
limited. However, the registry needs to be evaluated and
modified in term of its low sensitivity. Another limitation is
that these results are not validated against another dataset.
However, the gradient boosting method is a supervised
learning method and the data used were divided into two
sets, train and test, to avoid potential overfittings. Thus, it
focuses on increasing the external validity of the results.
Several determinantsmight be different between Iran and the
other countries including the pattern of referral to the hos-
pital, the average time from primary signs to hospital referral
as well as the public educational programs, and health
policy-maker decisions. This might be even considered as
explanation for a slight different reportedmodel performance
of the suggested prediction model in this sample.
Conclusion. In summary, lymphocytepercentage, elevated
BUN, aPTT, neutrophil percentage, and older age were the
most important predictors of in-hospital mortality in patients
with COVID-19 in Isfahan, Iran. The suggested model may
help identify patientswith poor prognosis andmaybe useful in
making decision to patient’s hospitalization where the prob-
ability of mortality may be more obvious based on the final
variable.
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